04/13/2023 1www.cdr.fi

Small animal molecular imaging unit

Core service for in vivo imaging method development and drug research

Faculty of Pharmacy/ SPECT-CT/ CDR

www.cdr.fi 04/13/2023 2Faculty of Pharmacy/ SPECT-CT/ CDR

Unique Molecular Imaging Capabilities

Therapeutic areas Oncology

CNS

Drug delivery

Cardiovascular

Inflammation

Early-Toxicology

Single Photon Emission Computed Tomography (SPECT)

NanoSPECT/CTFunctional & anatomical

imager

04/13/2023 3Faculty of Pharmacy/ Name / CDR

We provide the instruments and expertise for real-time visualization of molecules in vivo in small animals

SPECT/CT non-clinical imaging studies

Project specific services: Medical physics, radiopharmacy, biology

Consultation and training on molecular imaging in drug development

Collaborations are encouraged

Small Animal Molecular Imaging Unit

Services:

Facility:

SPECT/CT (NanoSPECT/CT with 4 heads, Bioscan Inc.).

Isotope laboratory with authorization to carry out animal research including viral vectors (Biosafety level 2 laboratory).

Funding bodies:

www.cdr.fi 04/13/2023 4Faculty of Pharmacy/ SPECT-CT/ CDR

Nanoparticle-Assisted in vivo Brain Imaging

www.cdr.fi 04/13/2023 5Faculty of Pharmacy/ SPECT-CT/ CDR

Biodistribution of [99mTc]-labelled Stealth Liposomes in Tumor-Bearing Mice

s.c. model i.p. model free labelLehtinen J, Raki M, Bergström KA, Uutela P, et al. (2012) Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma. PLoS ONE 7(7): e41410.http://www.plosone.org/article/info:doi/10.1371/journal.pone.0041410

Tumors

www.cdr.fi 04/13/2023 6Faculty of Pharmacy/ SPECT-CT/ CDR

Rodent Brain Imaging of Dopamine Transporter Ligand [123I]β-CIT

unlesioned 6-OHDA

Striatal uptake 4h after i.v. administration

Modified from: “Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT”

Pitkonen M., Hippeläinen E., Raki M., Andressoo J, Urtti A, Männistö P, Savolainen S., Saarma M., Bergström K. EJNMMI Research 2012, 2:55

From S. Bäck et al., Division of Pharmacology and Toxicology, University of Helsinki

www.cdr.fi 04/13/2023 7Faculty of Pharmacy/ SPECT-CT/ CDR

Dual Isotope Imaging of [123I]-NaI Release from [99mTc]-labelled Biomaterial

[99mTc]-labelled Biomaterial

[123I]-NaI

www.cdr.fi 04/13/2023 8Faculty of Pharmacy/ SPECT-CT/ CDR

Biodistribution of [99mTc]-labelled Bone Marrow-Derived Mesenchymal Stem Cells in Stroke Model

Rats subjected to middle cerebral artery occulsion 24 hours before cell delivery

Majority of the stem cells are located in the ischemic hemisphere 30 min after intra-arterial infusion

Taken from: Raki, M. et al.,: Cell-based therapies in stroke. Springer-Verlag. In press.

www.cdr.fi 04/13/2023 9Faculty of Pharmacy/ SPECT-CT/ CDR

Preclinical to Clinical: in vivo brain imaging from Mice to Men

24 h

1 h 4 h

Dopamine D2 DAT

Mouse

Human

Clinical images courtesy J. Kuikka

www.cdr.fi 04/13/2023 10Faculty of Pharmacy/ SPECT-CT/ CDR

CT Applications

CT images 8 week after surgical s.c. implantation of biomaterial granules

Waselau M, et al. (2012) In vivo Effects of Bioactive Glass S53P4 or Beta Tricalcium Phosphate on Osteogenic Differentiation of Human Adipose Stem Cells after Incubation with BMP-2. J Stem Cell Res Ther 2:125.

No contrast agent

Vascular contrast agent

Silvola J, et al. (2011) Uptake of 68gallium in atherosclerotic plaques in LDLR-/-ApoB100/100 mice. EJNMMI Research 1:14

www.cdr.fi 04/13/2023 11Faculty of Pharmacy/ SPECT-CT/ CDR

Research collaboration:IMI COMPACT consortium partners

04/13/2023 11

• 7 EFPIA partners:

• 16 Academic and Biotech partners• University of Helsinki/CDR• Utrecht University Dept. of

Pharmaceutics• University of Zurich• University of Copenhagen• Cardiff School of Pharmacy and

Pharmaceutical Sciences• Stockholm University• Norwegian Technical University• University of Vienna

• Helmholtz Inst. for Pharmaceutical Research Saarland

• Utrecht University Veterinary Immunology

• LMU Munich, Dept. of Pharmacy

• University of Ghent• PharmacoIdea Ltd.• BioneerPharma• Leiden University• Oxford University

www.cdr.fi 04/13/2023 12Faculty of Pharmacy/ SPECT-CT/ CDR

• Theranostics imaging and therapy - an action to develop novel nanosized systems for imaging-guided drug delivery

• Chair of the Action:

• Professor Silvio Aime, University of Turin, Italy

• Industries expressing an interest in the COST TD1004 Action:

• Imaging SpA

• Bayer Healthcare Pharmaceuticals

• GE Healthcare

• Siemens Healthcare

• Guerbet

• Philips Diagnostics

Research Collaboration:COST Action TD1004

www.cdr.fi 04/13/2023 13Faculty of Pharmacy/ SPECT-CT/ CDR

• Helsinki University Hospital (HUS Medical Imaging)

• BIU (Biomedicum Imaging Unit), University of Helsinki, Finland

• University of Helsinki, Finland

• Arto Urtti, Maart Saarma, Pekka Männistö, Raimo Tuominen, Marjo Yliperttula, Anu Airaksinen

• University of Tarto, Estonia

• Pille Taba

• Regea Cell and Tissue Center, University of Tampere, Finland

• Susanne Miettinen, Martin Waselau

• University of Turku, Finland

• Anne Roivainen

• University of Eastern Finland• Jukka Jolkkonen

• Finnish Red Cross Blood Service

• Saara Laitinen

Research Collaboration:Domestic and Regional Partners

www.cdr.fi 04/13/2023 14Faculty of Pharmacy/ SPECT-CT/ CDR

• SPECT/CT enables real-time morphological imaging and tracking of radiolabeled substances in rodents at ultra-high resolution (< 0.5 mm), quantitatively, & in 3D.

• It is suitable for a variety of research applications in oncology, neurology, cardiovascular pharmacology, target discovery, & gene expression studies; and, also for pharmacodynamic, pharmacokinetic, and morphological measurements.

• We welcome industrial and academic collaborations in method development, and we also provide fee-based contract imaging services. We offer:

Consultation, development, and execution of tailored experimental protocols or specific portions of experimental protocols.

Radiochemical and radiopharmacy services for the synthesis of SPECT tracers

On-site facilities for housing and maintenance of the users’ animals. All aspects of care & handling can be arranged.

Expertise of hospital physicist and access to MRI can be arranged for studies as needed.

We take responsibility for use of radioactive materials, and we ensure appropriate logistics for radioactive material and radioactive waste.

Summary

Contact: Paul Bromann, PhD paul.bromann@helsinki.fi www.CDR.fi